Skip Navigation


Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(10):1695-1701; doi:10.1093/annonc/mdi318
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/10/1695    most recent
mdi318v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hansma, A. H. G.
Right arrow Articles by Hoekman, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansma, A. H. G.
Right arrow Articles by Hoekman, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

A. H. G. Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo and K. Hoekman

Vrije Universiteit Medical Center, Department of Medical Oncology, Amsterdam, The Netherlands

Correspondence to: Dr K. Hoekman, Vrije Universiteit Medical Center, Department of Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel: +31-20-4444319; Fax: +31-20-4444355; E-mail: k.hoekman{at}vumc.nl.

Background: Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study.

Patients and methods: We determined the safety and pharmacokinetic profile of 4-week continuous intravenous infusion of recombinant human (rh)-endostatin, followed after an interval of 1 week by twice daily subcutaneous injections in patients with advanced cancer. Thirty-two patients received rh-endostatin in six dosing cohorts, ranging from 3.75 mg/m2/day to 120 mg/m2/day. Serum endostatin pharmacokinetics, toxicity and antitumor response were determined.

Results: A total of 160 cycles were delivered without significant toxicities. Pharmacokinetic analysis showed a linear increase of steady-state serum endostatin concentrations with dose (i.v. r2 = 0.96; s.c. r2 = 0.99) reaching 300–1000 ng/ml for the two highest doses, with considerable interpatient variation. The main pharmacokinetic values for both routes of administration were similar. The apparent steady-state concentration and AUC reached at 60–120 mg/m2/day were within the range expected to induce anti-angiogenic and antitumor effects based on preclinical tumor models. Although no objective responses were observed, two patients had long-lasting stable disease (defined as a tumor increase < 100%).

Conclusion: rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m2/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m2/day and above.

Key words: angiogenesis, endostatin, pharmacokinetics, phase I


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al.
Angiogenesis-independent tumor growth mediated by stem-like cancer cells
PNAS, October 31, 2006; 103(44): 16466 - 16471.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al.
Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol., August 1, 2006; 24(22): 3555 - 3561.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.